Prolaris test aids in decision making on multimodal therapy in prostate cancer

“I find [the Prolaris test] to be a very helpful clinical tool,” says Jonathan D. Tward, MD, PhD.

In this video, Jonathan D. Tward, MD, PhD, discusses findings from the study, “Association of the clinical cell-cycle risk score with metastasis after radiation therapy and identification of men with prostate cancer who can forgo combined androgen deprivation therapy,” which was presented at the 2021 Genitourinary Cancers Symposium. Tward is a professor of radiation oncology at the University of Utah, Salt Lake City.